Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study.

The pharmacogenomics journal - 22 Nov 2024

Li Yue, Wan Qing, Wan Jiaqi, Xiao Xiong, Hu Jinfang, Yang Xintong, Kong Fancong, Wang Jieyu, Song Baoquan, Li Zhentao, Li Fei, Ren Simei, Peng Hongwei

Abstract excerpt

Venetoclax (VEN) was the only Bcl-2 inhibitor approved yet and showed large differences in clinical efficacy. The aim of the study was to explore the relationships between the plasma concentration and efficacy of VEN, and identify potential influencing factors. A retrospective cohort study was conducted and a total of 76 trough (C0h) and 91 6 h post-dose plasma concentration (C6h) blood concentrations of VEN were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Leukemia

Share to Pharmacogenetics

Share to Sulfonamides

Share to Treatment Outcome

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 39578425
DOI: 10.1038/s41397-024-00359-6
PMCID: PMC11584383

Genes

CYP3A5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study.PMID 39578425Read ↗

Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective studySemantic proximity Read ↗

Association Between Venetoclax Concentration and Febrile Neutropenia in Acute Leukemia: A Retrospective AnalysisSemantic proximity Read ↗

Association Between Venetoclax Concentration and Febrile Neutropenia in Acute Leukemia: A Retrospective AnalysisSemantic proximity Read ↗

The Spectrum of Venetoclax-Based Treatments in Acute Myeloid LeukemiaSemantic proximity Read ↗

Effect of oral posaconazole on venetoclax plasma concentration and efficacy in patients with acute myeloid leukemiaSemantic proximity Read ↗

Reduced Duration and Dosage of Venetoclax Is Efficient in Newly Diagnosed Patients with Acute Myeloid LeukemiaSemantic proximity Read ↗

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemiaSemantic proximity Read ↗

Clinical Experience With Venetoclax in Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia.Semantic proximity Read ↗

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity Read ↗

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity Read ↗

Real-life Multicenter Experience of Long-term Treatment With Venetoclax Plus Azacitidine for Acute Myeloid Leukemia in ChinaSemantic proximity Read ↗

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.